BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20567114)

  • 1. [Long-term survival of a breast cancer patient with liver metastasis treated with trastuzumab and Paclitaxel].
    Ota Y; Ishikawa T; Yamada A; Shimizu D; Hasegawa S; Chishima T; Endo I
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1091-4. PubMed ID: 20567114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A long-term survival case of metastatic breast cancer treated with trastuzumab and paclitaxel].
    Ogino T; Komoike Y; Ishitobi M; Motomura K; Inaji H; Koyama H
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2234-6. PubMed ID: 19106581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A case of paclitaxel and trastuzumab-resistant recurrent breast cancer with liver metastasis responding to S-1].
    Nomura T; Sonoo H; Miyake A; Souda M; Yamamoto Y; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Kurebayashi J
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1607-10. PubMed ID: 18799922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A case of liver metastasis of breast cancer responding to trastuzumab plus weekly paclitaxel chemotherapy maintaining CR for 30 months].
    Nagahisa Y; Imai S; Yamaguchi K; Okabe M; Tsuruta A; Kawamoto K; Niwano M; Sano K; Park T; Yoshida Y; Ito T; Ogasahara K
    Gan To Kagaku Ryoho; 2007 Sep; 34(9):1501-3. PubMed ID: 17876156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
    Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
    Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.
    Hayashi H; Kimura M; Yoshimoto N; Tsuzuki M; Tsunoda N; Fujita T; Yamashita T; Iwata H
    Breast Cancer; 2009; 16(2):136-40. PubMed ID: 18548321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preoperative therapy using trastuzumab and weekly paclitaxel in a stage IIIB inoperable locally advanced HER2- positive breast cancer with complete pathologic response].
    Rai Y; Sagara Y; Ooi Y; Sagara Y; Sagara Y; Baba S; Tamada S; Matsuyama Y; Ando M
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):471-3. PubMed ID: 19295274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term survival of a patient with giant liver metastatic breast cancer treated with trastuzumab].
    Okada N; Narita Y; Nanno Y; Shimaguchi M; Imamura K; Inoue R; Nakamura T; Takada M; Kato H; Suzuki O; Ambo Y; Nakamura F; Kishida A; Kashimura N; Matsunami O
    Gan To Kagaku Ryoho; 2012 Sep; 39(9):1399-402. PubMed ID: 22996777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
    Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
    Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
    J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
    Shigematsu H; Nakamura Y; Tanaka K; Shiotani S; Koga C; Kawaguchi H; Nishimura S; Taguchi K; Nishiyama K; Ohno S
    Int J Clin Oncol; 2010 Dec; 15(6):615-20. PubMed ID: 20473628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.
    Kunitomo K; Inoue S; Ichihara F; Kono K; Fujii H; Matsumoto Y; Ooi A
    Hum Pathol; 2004 Mar; 35(3):379-81. PubMed ID: 15017597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
    Burstein HJ; Harris LN; Gelman R; Lester SC; Nunes RA; Kaelin CM; Parker LM; Ellisen LW; Kuter I; Gadd MA; Christian RL; Kennedy PR; Borges VF; Bunnell CA; Younger J; Smith BL; Winer EP
    J Clin Oncol; 2003 Jan; 21(1):46-53. PubMed ID: 12506169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bi-weekly nab-paclitaxel and trastuzumab therapy effective against recurrent breast cancer with multiple lung metastases in elderly patient who had previously undergone two chemotherapeutic regimens for treatment of metastatic disease-a case Report].
    Sakurai T; Jinta E; Suzuma T; Yoshimura G; Umemura T; Sakurai T
    Gan To Kagaku Ryoho; 2012 Nov; 39(11):1703-6. PubMed ID: 23152023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A case of advanced accessory breast cancer effectively treated with trastuzumab and paclitaxel].
    Suzuki S; Ohchi T; Doi K; Ogata K; Maeda T; Kudo K; Ishihara A
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1615-7. PubMed ID: 18799924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A long-surviving case of HER2-positive breast cancer with brain metastasis treated by multidisciplinary therapy].
    Sugimoto H; Nakagawa T; Sato T; Nagahara M; Ishiba T; Kasahara M; Kawachi H; Kubota K; Sugihara K
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):2071-3. PubMed ID: 23267980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer.
    Horiguchi J; Oyama T; Koibuchi Y; Yokoe T; Takata D; Ikeda F; Nagaoka H; Rokutanda N; Nagaoka R; Ishikawa Y; Odawara H; Kikuchi M; Sato A; Iino Y; Takeyoshi I
    Anticancer Res; 2009 Feb; 29(2):517-24. PubMed ID: 19331197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination treatment with trastuzumab and Paclitaxel as primary therapy for advanced breast cancer].
    Suzuki M; Kimijima I; Ishii M
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1519-23. PubMed ID: 19755824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.